Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: Results from a 52-week, randomized, double-blind, placebo-controlled study

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Donohue, James F ^a   Niewoehner, Dennis ^b   Brooks, Jean ^c   O'Dell, Dianne ^d   Church, Alison ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b VA MEDICAL CENTER   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Bronchodilator; Combination; Long acting muscarinic antagonist

Indexed keywords

BENZYL ALCOHOL DERIVATIVE; CHLOROBENZENE; DRUG COMBINATION; QUINUCLIDINE DERIVATIVE; UMECLIDINIUM; VILANTEROL; ANTIBIOTIC AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; UMECLIDINIUM PLUS VILANTEROL;

AGED; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL; ABNORMAL LABORATORY RESULT; ADULT; ADVERSE DRUG REACTION; ANTICHOLINERGIC SYNDROME; ARTICLE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GALLBLADDER DISEASE; HEART ATRIUM ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HOLTER MONITORING; HYPERGLYCEMIA; INCIDENCE; INTESTINE OBSTRUCTION; LOBAR PNEUMONIA; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; PNEUMONIA; RHINOPHARYNGITIS; SUPRAVENTRICULAR PREMATURE BEAT; SUPRAVENTRICULAR TACHYCARDIA; TREMOR; URINE RETENTION; VIRAL BRONCHITIS; VIRUS INFECTION; VITAL SIGN;

AGED; BENZYL ALCOHOLS; CHLOROBENZENES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES;

EID: 84904081919     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-15-78     Document Type: Article

References (28)

1. Celli BR, MacNee W, . ATS/ERS Task Force Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946. 10.1183/09031936.04.00014304, 15219010, ATS/ERS Task Force.
2. GOLD Global strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease. 2014, [http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf], GOLD.
3. Brusasco V. Reducing cholinergic constriction: the major reversible mechanism in COPD. Eur Respir Rev 2006, 15:32-36.
4. Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010, 23:257-267. 10.1016/j.pupt.2010.03.003, 20381630.
5. Mahler DA, D'Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B, . INTRUST-1 and INTRUST-2 study investigators Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012, 67:781-788. 10.1136/thoraxjnl-2011-201140, 22544891, INTRUST-1 and INTRUST-2 study investigators.
6. van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012, 21:101-108. 10.4104/pcrj.2011.00102, 22222945.
7. van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, Overend T. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010, 65:1086-1091. 10.1136/thx.2010.139113, 20978028.
8. Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, Alam T. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012, 18:527-539.
9. Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med 2012, 106:970-979. 10.1016/j.rmed.2012.03.012, 22498110.
10. Hanania NA, Feldman G, Zachgo W, Shim JJ, Crim C, Lettis S, Barnhart F, Haumann B. The efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest 2012, 142:119-127. 10.1378/chest.1388838, 22241764.
11. Donohue J, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013, 107:1538-1546. 10.1016/j.rmed.2013.06.001, 23830094.
12. Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, Church A. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014, 145:981-991.
13. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1). 1996, [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf], International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
14. World Medical Association WMA Declaration of Helsinki - ethical principles for medical research involving human subjects. 2008, [http://www.wma.net/en/30publications/10policies/b3/index.html], World Medical Association.
15. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999, 159:179-187. 10.1164/ajrccm.159.1.9712108, 9872837.
16. Hanania N, Donohue J, Make B. A long term safety study of arformoterol tartrate in the maintenance therapy of patients with moderate to severe COPD: incidence of adverse events. Am J Respir Crit Care Med 2013, 187:A1482.
17. Donohue JF, Hanania NA, Sciarappa KA, Goodwin E, Grogan DR, Baumgartner RA, Hanrahan JP. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis 2008, 2:37-48. 10.1177/1753465808089455, 19124357.
18. Donohue JF, Hanania NA, Fogarty C, Campbell SC, Rinehard M, Denis-Mize K. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis 2008, 2:199-208. 10.1177/1753465808093934, 19124372.
19. Make B, Hanania N, Donohue J. A long term safety study of arformoterol tartrate in the maintenance therapy of patients with moderate to severe COPD: evaluation of lung function. Am J Respir Crit Care Med 2013, 187:A1481.
20. Donohue J, Hanania N, Make B, Curry L. A long term safety study of arformoterol tartrate in the maintenance therapy of patients with moderate to severe COPD: incidence of respiratory-related deaths and COPD exacerbation-related hospitalizations. Am J Respir Crit Care Med 2013, 187:A2436.
21. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002, 19:217-224. 10.1183/09031936.02.00269802, 11866001.
22. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B, . INDORSE Study Investigators Long-term safety and efficacy of indacaterol, a long-acting beta(2)-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011, 140:68-75. 10.1378/chest.10-1830, 21349928, INDORSE Study Investigators.
23. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999, 115:957-965. 10.1378/chest.115.4.957, 10208192.
24. Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014, 2:472-486. 10.1016/S2213-2600(14)70065-7, 24835833.
25. Salpeter SR. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?. Drugs 2009, 69:2025-2033. 10.2165/11318580-000000000-00000, 19791824.
26. Anthonisen NR, Connett JE, Enright PL, Manfreda J, . Lung Health Study Research Group Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002, 166:333-339. 10.1164/rccm.2110093, 12153966, Lung Health Study Research Group.
27. Division of Pulmonary-Allergy Drugs Advisory Committee and Office of Surveillance and Epidemiology, US Food and Drug Administration FDA Briefing Document. 2009, [http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pulmonary-allergydrugsadvisorycommittee/ucm190463.pdf], Division of Pulmonary-Allergy Drugs Advisory Committee and Office of Surveillance and Epidemiology, US Food and Drug Administration.
28. Center for Drug Evaluation and Research (CDER) Medical reviews, aclidinium bromide. 2012, [http://www.accessdata.fda.gov/drugsatfdadocs/nda/2012/202450Orig1s000MedR.pdf], Center for Drug Evaluation and Research (CDER).